Coldstream Capital Management Inc Amgen Inc Transaction History

Coldstream Capital Management Inc

  • $4.07 Billion
  • Q2 2024

A detailed history of Coldstream Capital Management Inc transactions in Amgen Inc stock. As of the latest transaction made, Coldstream Capital Management Inc holds 27,936 shares of AMGN stock, worth $9 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares
27,936
Previous 26,720 4.55%
Holding current value
$9 Million
Previous $7.6 Million 14.89%
% of portfolio
0.21%
Previous 0.19%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024
BUY
$262.75 - $319.31 $319,504 - $388,280
1,216 Added 4.55%
27,936 $8.73 Million
Q1 2024

May 13, 2024
BUY
$268.87 - $324.56 $57,807 - $69,780
215 Added 0.81%
26,720 $7.6 Million
Q4 2023

Feb 09, 2024
BUY
$255.7 - $288.46 $3.03 Million - $3.42 Million
11,839 Added 80.72%
26,505 $7.63 Million
Q3 2023

Nov 02, 2023
BUY
$218.65 - $271.46 $967,307 - $1.2 Million
4,424 Added 43.19%
14,666 $3.94 Million
Q2 2023

Aug 03, 2023
SELL
$214.27 - $253.37 $51,639 - $61,062
-241 Reduced 2.3%
10,242 $2.27 Million
Q1 2023

May 15, 2023
SELL
$225.79 - $275.2 $56,447 - $68,800
-250 Reduced 2.33%
10,483 $2.53 Million
Q4 2022

Jan 10, 2023
SELL
$229.03 - $291.01 $1.1 Million - $1.4 Million
-4,798 Reduced 30.89%
10,733 $0
Q2 2022

Aug 08, 2022
BUY
$230.71 - $256.74 $776,569 - $864,186
3,366 Added 27.67%
15,531 $3.78 Million
Q2 2022

Aug 08, 2022
SELL
$230.71 - $256.74 $444,578 - $494,737
-1,927 Reduced 13.67%
12,165 $2.96 Million
Q1 2022

May 11, 2022
BUY
$219.27 - $242.57 $321,230 - $355,365
1,465 Added 11.6%
14,092 $3.41 Million
Q4 2021

Feb 11, 2022
SELL
$198.88 - $227.6 $1.31 Million - $1.5 Million
-6,577 Reduced 34.25%
12,627 $2.84 Million
Q3 2021

Nov 12, 2021
BUY
$212.27 - $248.7 $2.94 Million - $3.45 Million
13,870 Added 260.03%
19,204 $4.88 Million
Q2 2021

Aug 16, 2021
BUY
$233.58 - $259.14 $112,819 - $125,164
483 Added 9.96%
5,334 $1.3 Million
Q1 2021

Jun 16, 2021
SELL
$221.91 - $258.6 $2.93 Million - $3.41 Million
-13,195 Reduced 73.12%
4,851 $1.21 Million
Q4 2020

Feb 16, 2021
BUY
$216.38 - $257.67 $237,368 - $282,663
1,097 Added 6.47%
18,046 $4.15 Million
Q3 2020

Nov 16, 2020
BUY
$234.65 - $260.95 $23,934 - $26,616
102 Added 0.61%
16,949 $4.31 Million
Q2 2020

Aug 12, 2020
SELL
$197.81 - $242.74 $285,242 - $350,031
-1,442 Reduced 7.88%
16,847 $3.97 Million
Q1 2020

May 27, 2020
SELL
$182.24 - $241.7 $178,777 - $237,107
-981 Reduced 5.09%
18,289 $3.71 Million
Q4 2019

Feb 13, 2020
BUY
$189.21 - $243.2 $36,895 - $47,424
195 Added 1.02%
19,270 $4.65 Million
Q3 2019

Nov 15, 2019
BUY
$174.11 - $208.62 $121,528 - $145,616
698 Added 3.8%
19,075 $3.69 Million
Q2 2019

Aug 15, 2019
SELL
$166.7 - $195.41 $25,505 - $29,897
-153 Reduced 0.83%
18,377 $3.39 Million
Q1 2019

May 10, 2019
BUY
$180.87 - $203.88 $221,927 - $250,160
1,227 Added 7.09%
18,530 $3.52 Million
Q4 2018

Feb 26, 2019
BUY
$178.4 - $208.25 $76,176 - $88,922
427 Added 2.53%
17,303 $3.37 Million
Q3 2018

Nov 14, 2018
BUY
$185.29 - $208.89 $133,964 - $151,027
723 Added 4.48%
16,876 $3.5 Million
Q2 2018

Aug 14, 2018
BUY
$166.05 - $186.51 $48,652 - $54,647
293 Added 1.85%
16,153 $2.98 Million
Q1 2018

May 16, 2018
SELL
$169.43 - $198.0 $99,455 - $116,226
-587 Reduced 3.57%
15,860 $2.7 Million
Q4 2017

Feb 14, 2018
BUY
$168.79 - $188.59 $87,602 - $97,878
519 Added 3.26%
16,447 $2.86 Million
Q3 2017

Nov 15, 2017
BUY
$167.29 - $191.0 $162,271 - $185,270
970 Added 6.48%
15,928 $2.97 Million
Q2 2017

Aug 15, 2017
BUY
N/A
14,958
14,958 $2.58 Million

Others Institutions Holding AMGN

# of Institutions
3,055
Shares Held
409M
Call Options Held
7.19M
Put Options Held
6.26M
View Full List

About AMGEN INC

AMGN Quotes by TradingView
  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $172B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Coldstream Capital Management Inc Portfolio

Follow Coldstream Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Coldstream Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Coldstream Capital Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email